厄洛替尼联合鞘内化疗治疗非小细胞肺癌脑膜转移的临床效果.docVIP

厄洛替尼联合鞘内化疗治疗非小细胞肺癌脑膜转移的临床效果 　　[摘要] 目的 分析表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼治疗非小细胞肺癌脑膜转移的效果。 方法 收集我院确诊为非小细胞肺癌脑膜转移患者的病例进行回顾性分析，根据治疗方案将病例分为观察组（鞘内化疗联合厄洛替尼治疗组，17例）和对照组（鞘内化疗组，29例），对两组的治疗效果进行分析。 结果 观察组的脑脊液癌细胞转阴率为52.9%，对照组的脑脊膜癌细胞转阴率为24.1%，两组比较差异有统计学意义（P0.05）；观察组症状缓解率为64.7%，对照组的症状缓解率为31.0%，两组比较差异有统计学意义（P0.05）；观察组中位无进展生存期为5.3个月，对照组中位无进展生存期为3.4个月，两组比较差异有统计学意义（P0.05）。 结论 对于非小细胞肺癌脑膜转移，厄洛替尼治疗联合鞘内化疗能够取得较好的治疗效果。 　　[关键词] 非小细胞肺癌；脑膜转移；厄洛替尼 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721（2015）08（b）-0049-04 　　Clinical effect of Erlotinib in the treatment of non-small cell lung cancer with meningeal metastasis 　　YAN Wei-hong1 LI Yi2 LUO Qing-fen3 SUN Cheng-hui1▲ 　　1.Department of Oncology，People′s Hospital of Yangchun City，Guangdong Province，Yangchun 529600，China；2.Department of Otorhinolaryngology，People′s Hospital of Yangchun City，Guangdong Province，Yangchun 529600，China；3.Department of Four Surgery，People′s Hospital of Yangchun City，Guangdong Province，Yangchun 529600，China 　　[Abstract] Objective To analyze the function of Erlotinib in the treatment of non-small cell lung cancer with meningeal metastasis. Methods The cases diagnosed of non small cell lung cancer patients with leptomeningeal metastasis in our hospital were collected，and retrospective analysis was done.The patients were divided into observation group （intrathecal chemotherapy combined with Erlotinib treatment group，17 cases） and control group （intrathecal chemotherapy group，29 cases） according to the therapeutic regimen，and the curative effect of the cytologic conversion rate and symptom remission rate of the two groups were analyzed. Results The cytologic conversion rate of the observation group and the control group was 52.9% and 24.1%，and the difference was statistically significant （P0.05）；the symptom remission rate of the observation group and the control group was 64.7% and 31.0%，the difference was statistically significant （P0.05）；the medianprogression-free survival of the observation group and the control group was 5.3 m